Immutep (IMMP) Stock: Buy, Sell, or Hold?
IMMP - Immutep Limited American Depositary Shares
$0.37
0.05 (14.83%)
â˛
5d:
+2.25%
30d:
-2.56%
90d:
+3.32%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Sep 04, 2026
0d
Get Alerted When IMMP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: IMMP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: IMMP is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: IMMP is currently trading at $0.37, which is considered fair relative to its 30-day fair value range of $0.36 to $0.39.
Technical Outlook: Technically, IMMP is in a downtrend. Immediate support is located at $0.33, while resistance sits at $0.41. The stock is showing strong short-term momentum, up 14.8% recently.
Market Sentiment: IMMP scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.50 (+301.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMMP is in a downtrend. Immediate support is located at $0.33, while resistance sits at $0.41. The stock is showing strong short-term momentum, up 14.8% recently.
Market Sentiment: IMMP scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1.50 (+301.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.36 -
$0.39
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+14.8%)
- BULLISH: Trading 301.8% below Wall St target ($1.50)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.36 -
$0.39
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.33
Resistance Level
$0.41
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.44
Wall Street Target
$1.50
(+301.8%)
Revenue Growth (YoY)
633.5%
Share & Embed Analysis
Last updated: September 13, 2026 5:36 AM ET
Data refreshes hourly during market hours. Next update: 6:36 AM
Data refreshes hourly during market hours. Next update: 6:36 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMMP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
